Clinical trials: Metastatic Brain Cancer
Brain Metastases, Adult
Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin
The occurrence of brain metastases (BMs) is increasing given the availability of a more accurate radiological imaging such as MRI for detecting also small brain lesions and the most effective systemic therapy able to control…
- Trial name
- NCT05793489
- Testing
- Silibinin
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Istituto Clinico Humanitas
Brain Metastasis
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
The incidence of brain metastasis of Her2-negative breast cancer is high, which seriously affects the prognosis of patients.The treatment of brain metastasis of Her2-negative breast cancer is still tricky.
- Trial name
- NCT06462079
- Testing
- Sacituzumab Govitecan, Radiotherapy
- Volunteers
- 43 people
- Sponsor
- Guangzhou Medical University
Tumors Metastatic to Brain, Unspecified Adult Solid Tumor, Protocol Specific
Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery
This pilot clinical trial studies how well voxel based diffusion tensor imaging in predicting response in patients with brain metastases undergoing whole-brain radiation therapy or stereotactic radiosurgery.
- Trial name
- NCT02277561
- Testing
- diffusion tensor imaging, whole-brain radiation therapy, stereotactic radiosurgery
- Where
- United States
- Sponsor
- Albert Einstein College of Medicine
Lung Cancer, Breast Cancer
Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases
For patients with 1-6 intraparenchymal brain metastases from various primary histologies (except for melanoma), stereotactic radiosurgery (administered upfront or concurrently) or complete surgical resection with neural stem cell…
- Conditions
- Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT00581113
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Virginia Commonwealth University
Brain Metastasis, Stereotactic Radiosurgery
OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy
To remove a brain tumor, patients usually receive radiation to lower the chance that the cancer will come back in the spot where the tumor was removed.
- Conditions
- Brain Metastasis, Stereotactic Radiosurgery, Resection, Systemic Therapy
- Trial name
- NCT07655583
- Testing
- Systemic therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of the combination of tesevatinib and trastuzumab in subjects with HER2-positive metastatic breast cancer
- Trial name
- NCT02154529
- Testing
- Tesevatinib, Trastuzumab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kadmon Corporation, LLC
Radionecrosis of Brain, Brain Metastases
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
Brain metastases (BM) afflict a significant portion of cancer patients, ranging from 10% to 50%, leading to debilitating symptoms and diminished quality of life, thereby impacting overall survival.
- Trial name
- BRADI (NCT06471465)
- Testing
- Bevacizumab, Prednisolone
- Where
- 10 sites in France
- Volunteers
- 84 people
- Sponsor
- Institut Cancerologie de l'Ouest
Brain Metastasases
A Study of Stereotactic Radiosurgery (SRS) in People With Brain Cancer Having Tumor Resection Surgery
The researchers are doing this study to see if treating people's brain tumors with stereotactic radiosurgery (SRS) before tumor resection surgery will prevent cancer cells from spreading to other areas of the brain, including the…
- Trial name
- NCT07802353
- Testing
- Stereotactic Radiosurgery, Surgical Resection
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors
RATIONALE: Questionnaires that measure quality of life may improve the ability to plan treatment for patients with primitive neuroectodermal tumors.
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00278239
- Testing
- cognitive assessment, psychosocial assessment and care, quality-of-life assessment
- Where
- 21 sites in Ireland, United Kingdom
- Sponsor
- Children's Cancer and Leukaemia Group
Cognitive/Functional Effects, Metastatic Cancer
Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00910039
- Testing
- sunitinib malate, cognitive assessment
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Brain Metastases
An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
This is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in patients with BRAFV600-mutant melanoma with brain…
- Trial name
- POLARIS (NCT03911869)
- Testing
- encorafenib, binimetinib
- Where
- 25 sites in United States, Argentina and 3 more
- Volunteers
- 13 people
- Sponsor
- Pfizer
Brain Metastases, Adult, Non Small Cell Lung Cancer
SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).
- Conditions
- Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer
- Trial name
- SILMET (NCT05689619)
- Testing
- Silibinin
- Where
- 6 sites in Italy
- Volunteers
- 70 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
NSCLC
Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases
The purpose of this study is to evaluate the safety profile and efficacy of whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ) in patients with brain metastases (BM).Patients with BM were randomly assigned to…
- Trial name
- NCT02385136
- Testing
- Temozolomide
- Volunteers
- 135 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Neoplasm, Brain Neoplasm
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.
- Conditions
- Breast Neoplasm, Brain Neoplasm, Second Neoplasm
- Trial name
- STOP (NCT00638963)
- Testing
- temozolomide
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Melanoma
A Study of LN-144 in People With Metastatic Melanoma to the Brain
This is an open label study evaluating lifileucel (LN-144) in patients with melanoma brain metastases.
- Trial name
- NCT05640193
- Testing
- Lifileucel (LN-144)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Metastasis, Non-small Cell Lung Cancer
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
The study objective is to evaluate the safety and efficacy of patupilone with respect to early progression and response of patients with non-small cell lung cancer (NSCLC) metastatic to the brain, who have progressed after…
- Trial name
- NCT00219297
- Testing
- Patupilone
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Brain Metastases, Leptomeningeal Metastasis
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy
This is a prospective, single-center, phase 1 basket trial that will evaluate the safety and feasibility of administering SV-BR-1-GM in combination with pembrolizumab to solid tumor oncology patients over nine cycles.
- Trial name
- NCT07199413
- Testing
- SV-BR-1-GM Vaccine, Cyclophosphamide, Pembrolizumab
- Sponsor
- Medical College of Wisconsin
Brain (Nervous System) Cancers, Brain and Central Nervous System Tumors
Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors
MT027 is an off-the-shelf, allogeneic chimeric antigen receptor T cell (UCAR-T) injection prepared from healthy donor T cells targeting B7-H3.
- Conditions
- Brain (Nervous System) Cancers, Brain and Central Nervous System Tumors, Brain Tumors
- Trial name
- NCT06742593
- Testing
- MT027 cells suspension
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Suzhou Maximum Bio-tech Co., Ltd.
NSCLC Stage IV, Brain Metastases
Genomic Study in Non-small Cell Lung Cancer Brain Metastasis
The investigators collected the data from the investigators' center between January 2011 and October 2020. The study included all non-small cell lung cancer patients with surgically excised brain metastasis.
- Trial name
- NCT04745715
- Testing
- craniectomy
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- National Cheng-Kung University Hospital
Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer
ARRY-380 + Trastuzuamab for Breast w/ Brain Mets
The purpose of this study is to test the safety of different doses of ARRY-380 in combination with trastuzumab. Trastuzumab is an FDA approved drug for the treatment of HER2 metastatic breast cancer.
- Trial name
- NCT01921335
- Testing
- ARRY-380 Twice Daily Dosage, ARRY-380 Once Daily, Trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Dana-Farber Cancer Institute